List of Tables
Table 1. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Nasal Spray Live Attenuated Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
Table 7. Global Nasal Spray Live Attenuated Vaccine Sales by Region (2020-2025) & (K Dose)
Table 8. Global Nasal Spray Live Attenuated Vaccine Sales by Region (2026-2031) & (K Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Nasal Spray Live Attenuated Vaccine Sales by Manufacturers (2020-2025) & (K Dose)
Table 11. Global Nasal Spray Live Attenuated Vaccine Sales Share by Manufacturers (2020-2025)
Table 12. Global Nasal Spray Live Attenuated Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Nasal Spray Live Attenuated Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nasal Spray Live Attenuated Vaccine as of 2024)
Table 16. Global Nasal Spray Live Attenuated Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Nasal Spray Live Attenuated Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Nasal Spray Live Attenuated Vaccine Manufacturing Base and Headquarters
Table 19. Global Nasal Spray Live Attenuated Vaccine Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Nasal Spray Live Attenuated Vaccine Sales by Type (2020-2025) & (K Dose)
Table 23. Global Nasal Spray Live Attenuated Vaccine Sales by Type (2026-2031) & (K Dose)
Table 24. Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Nasal Spray Live Attenuated Vaccine ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Nasal Spray Live Attenuated Vaccine Sales by Application (2020-2025) & (K Dose)
Table 29. Global Nasal Spray Live Attenuated Vaccine Sales by Application (2026-2031) & (K Dose)
Table 30. Nasal Spray Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Nasal Spray Live Attenuated Vaccine ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 37. North America Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 40. Europe Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
Table 45. Southeast Asia Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Nasal Spray Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 47. Central and South America Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Nasal Spray Live Attenuated Vaccine Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. AstraZeneca Corporation Information
Table 51. AstraZeneca Description and Major Businesses
Table 52. AstraZeneca Product Models, Descriptions and Specifications
Table 53. AstraZeneca Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. AstraZeneca Sales Value Proportion by Product in 2024
Table 55. AstraZeneca Sales Value Proportion by Application in 2024
Table 56. AstraZeneca Sales Value Proportion by Geographic Area in 2024
Table 57. AstraZeneca Nasal Spray Live Attenuated Vaccine SWOT Analysis
Table 58. AstraZeneca Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Nasal Spray Live Attenuated Vaccine SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. CSL Corporation Information
Table 69. CSL Description and Major Businesses
Table 70. CSL Product Models, Descriptions and Specifications
Table 71. CSL Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 72. CSL Sales Value Proportion by Product in 2024
Table 73. CSL Sales Value Proportion by Application in 2024
Table 74. CSL Sales Value Proportion by Geographic Area in 2024
Table 75. CSL Nasal Spray Live Attenuated Vaccine SWOT Analysis
Table 76. CSL Recent Developments
Table 77. BioDiem Corporation Information
Table 78. BioDiem Description and Major Businesses
Table 79. BioDiem Product Models, Descriptions and Specifications
Table 80. BioDiem Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 81. BioDiem Sales Value Proportion by Product in 2024
Table 82. BioDiem Sales Value Proportion by Application in 2024
Table 83. BioDiem Sales Value Proportion by Geographic Area in 2024
Table 84. BioDiem Nasal Spray Live Attenuated Vaccine SWOT Analysis
Table 85. BioDiem Recent Developments
Table 86. SEQIRUS, INC. Corporation Information
Table 87. SEQIRUS, INC. Description and Major Businesses
Table 88. SEQIRUS, INC. Product Models, Descriptions and Specifications
Table 89. SEQIRUS, INC. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 90. SEQIRUS, INC. Sales Value Proportion by Product in 2024
Table 91. SEQIRUS, INC. Sales Value Proportion by Application in 2024
Table 92. SEQIRUS, INC. Sales Value Proportion by Geographic Area in 2024
Table 93. SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine SWOT Analysis
Table 94. SEQIRUS, INC. Recent Developments
Table 95. Changchun BCHT Biotechnology Co. Corporation Information
Table 96. Changchun BCHT Biotechnology Co. Description and Major Businesses
Table 97. Changchun BCHT Biotechnology Co. Product Models, Descriptions and Specifications
Table 98. Changchun BCHT Biotechnology Co. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 99. Changchun BCHT Biotechnology Co. Recent Developments
Table 100. Serum Institute Corporation Information
Table 101. Serum Institute Description and Major Businesses
Table 102. Serum Institute Product Models, Descriptions and Specifications
Table 103. Serum Institute Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 104. Serum Institute Recent Developments
Table 105. Key Raw Materials Distribution
Table 106. Raw Materials Key Suppliers
Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 108. Milestones in Production Technology Evolution
Table 109. Distributors List
Table 110. Market Trends and Market Evolution
Table 111. Market Drivers and Opportunities
Table 112. Market Challenges, Risks, and Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Nasal Spray Live Attenuated Vaccine Product Picture
Figure 2. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Trivalent Nasal Spray Live Attenuated Vaccine Product Picture
Figure 4. Quadrivalent Nasal Spray Live Attenuated Vaccine Product Picture
Figure 5. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospitals & Clinics
Figure 7. Public Health Organizations
Figure 8. Research Organizations
Figure 9. Others
Figure 10. Nasal Spray Live Attenuated Vaccine Report Years Considered
Figure 11. Global Nasal Spray Live Attenuated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 13. Global Nasal Spray Live Attenuated Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Region (2020-2031)
Figure 15. Global Nasal Spray Live Attenuated Vaccine Sales (2020-2031) & (K Dose)
Figure 16. Global Nasal Spray Live Attenuated Vaccine Sales (CAGR) by Region (2020-2031) (K Dose)
Figure 17. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Volume Market Share in 2024
Figure 19. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Trivalent Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturer in 2024
Figure 22. Quadrivalent Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturer in 2024
Figure 23. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Type (2020-2031)
Figure 24. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Type (2020-2031)
Figure 25. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Application (2020-2031)
Figure 26. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Application (2020-2031)
Figure 27. North America Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
Figure 28. North America Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
Figure 30. North America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020- 2031)
Figure 31. North America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
Figure 33. North America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 35. Canada Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 37. Europe Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
Figure 38. Europe Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
Figure 40. Europe Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020-2031)
Figure 41. Europe Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
Figure 43. Europe Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 45. France Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 47. Italy Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 48. Russia Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
Figure 50. Asia-Pacific Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020- 2031)
Figure 53. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
Figure 55. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 57. Japan Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 60. India Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
Figure 62. Central and South America Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2021-2031)
Figure 65. Central and South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
Figure 67. Central and South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
Figure 71. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2021-2031)
Figure 74. South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
Figure 76. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
Figure 81. Nasal Spray Live Attenuated Vaccine Industry Chain Mapping
Figure 82. Regional Nasal Spray Live Attenuated Vaccine Manufacturing Base Distribution (%)
Figure 83. Global Nasal Spray Live Attenuated Vaccine Production Market Share by Region (2020-2031)
Figure 84. Nasal Spray Live Attenuated Vaccine Production Process
Figure 85. Regional Nasal Spray Live Attenuated Vaccine Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed